Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
6.72M
-
Number of holders
-
32
-
Total 13F shares, excl. options
-
4.05M
-
Shares change
-
+1.06M
-
Total reported value, excl. options
-
$480K
-
Value change
-
-$31.4K
-
Number of buys
-
23
-
Number of sells
-
-11
-
Price
-
$0.12
Significant Holders of Conduit Pharmaceuticals Inc. - Common Stock, par value $0.0001 per share (CDT) as of Q3 2024
39 filings reported holding CDT - Conduit Pharmaceuticals Inc. - Common Stock, par value $0.0001 per share as of Q3 2024.
Conduit Pharmaceuticals Inc. - Common Stock, par value $0.0001 per share (CDT) has 32 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.05M shares
of 6.72M outstanding shares and own 60.25% of the company stock.
Largest 10 shareholders include BARCLAYS PLC (838K shares), BlackRock, Inc. (756K shares), GEODE CAPITAL MANAGEMENT, LLC (428K shares), VANGUARD GROUP INC (362K shares), Qube Research & Technologies Ltd (318K shares), CITADEL ADVISORS LLC (190K shares), NORTHERN TRUST CORP (185K shares), MORGAN STANLEY (184K shares), UBS Group AG (169K shares), and NEW YORK STATE COMMON RETIREMENT FUND (88.7K shares).
This table shows the top 32 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.